Viviane Dubruille

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies.

Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 12, 2025

Return to employment outcomes in patients with multiple myeloma.

Return to employment outcomes in patients with multiple myeloma.

Journal: British journal of haematology

Published: August 26, 2025

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

Journal: The Lancet. Haematology

Published: August 18, 2025

Sexual and reproductive life of men and women with chronic myeloid leukemia: Opinion and practical considerations of the Fi-LMC group

Sexual and reproductive life of men and women with chronic myeloid leukemia: Opinion and practical considerations of the Fi-LMC group

Journal: Bulletin du cancer

Published: June 04, 2025

Identification of Hepatic-like EPO as a Cause of Polycythemia.

Identification of Hepatic-like EPO as a Cause of Polycythemia.

Journal: The New England journal of medicine

Published: April 30, 2025

Extended long-term follow-up and the survival of Stop Imatinib study.

Extended long-term follow-up and the survival of Stop Imatinib study.

Journal: Blood neoplasia

Published: February 10, 2025

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.

Journal: Leukemia & lymphoma

Published: March 19, 2024

Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.

Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.

Journal: American journal of hematology

Published: August 22, 2023

Quad-class exposed/refractory myeloma is associated with short survival.

Quad-class exposed/refractory myeloma is associated with short survival.

Journal: British journal of haematology

Published: July 31, 2023

Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen.

Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen.

Journal: Haematologica

Published: March 15, 2023

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.

Journal: Blood advances

Published: November 10, 2022

Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Journal: British journal of haematology

Published: May 13, 2022

Showing 1-12 of 59

Last Updated: 09/26/2026